Loading…
Heron Therapeutics, Inc. is projected to rise to $0.4998 by 2027, a +1% move from its current price of $0.4962. HRTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $0.4804 | $0.496 | $0.5122 | -0.03% |
| Aug 5 | $0.4739 | $0.4959 | $0.5188 | -0.07% |
| Aug 6 | $0.469 | $0.4957 | $0.5239 | -0.10% |
| Aug 7 | $0.4648 | $0.4955 | $0.5282 | -0.14% |
| Aug 8 | $0.4611 | $0.4953 | $0.5321 | -0.17% |
| Aug 9 | $0.4578 | $0.4952 | $0.5355 | -0.21% |
| Aug 10 | $0.4548 | $0.495 | $0.5387 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4548 | $0.495 | $0.5387 | -0.24% |
| Week 2 | $0.4381 | $0.4938 | $0.5566 | -0.49% |
| Week 3 | $0.4254 | $0.4926 | $0.5704 | -0.73% |
| Week 4 | $0.4148 | $0.4914 | $0.582 | -0.97% |
| Week 5 | $0.4056 | $0.4902 | $0.5923 | -1.22% |
| Week 6 | $0.3974 | $0.489 | $0.6016 | -1.46% |
| Week 7 | $0.3899 | $0.4878 | $0.6102 | -1.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company in the healthcare sector that engages in developing and commercializing therapeutic that enhances medical care. Its products rely on Biochronomer, a drug-delivery technology that delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
The company markets SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide regimens, and CINVANTI, an intravenous formulation of aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Heron Therapeutics is also developing ZYNRELEF, a dual-acting local anesthetic, and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist for postoperative nausea and vomiting. The company was formerly known as A.P.
Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. It was founded in 1983 and is headquartered in Cary, North Carolina.
Heron Therapeutics, Inc. trades under the symbol HRTX and currently has a price of $0.476 with a market cap of $90.1M, ranking 4169 by market capitalization. The current price and market position reflect a small-cap biotechnology profile.
The year-by-year forecast shows a path from a flat near-term outlook in 2026 toward a higher long-term trajectory, with 2026 avg price of $0.476 and 0 ROI, rising to a 2030 avg of $0.6887 and a max of $1.10 (ROI 44.7), and continuing to higher levels by 2040 ($1.14 avg) and 2050 ($2.01 avg, max $4.37). These figures are estimates and subject to risk and uncertainty.
A major floor 23.4% below — a decisive break under it would weaken the trend.
The nearest floor, 17.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 164.0% above — clearing it would confirm fresh momentum.
Key HRTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HRTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.488 | Buy | $0.4902 | Buy |
| MA 10 | $0.479 | Buy | $0.4796 | Buy |
| MA 20 | $0.459 | Buy | $0.4725 | Buy |
| MA 50 | $0.5092 | Sell | $0.5504 | Sell |
| MA 100 | $0.7326 | Sell | $0.7105 | Sell |
| MA 200 | $0.9886 | Sell | $0.9533 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.43 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 117.82 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 13.64 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.40 | Sell |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 76.82 | Sell |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 0.50 | Sell |
| ADX (14) | 17.60 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 is 50, and the stock trades around a mid-range that sits between the SMA50 of $0.6298 and the SMA200 of $1.03. Near-term support is cited at $0.38 and resistance at $0.48.
The 30-day range runs from a low of $0.3652 to a high of $0.6205. Annualized volatility is high at 80%, indicating notable price movement potential even within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.38 | $0.4962 | $0.5829 | 0% | Neutral | |
| $0.3924 | $0.4998 | $0.6766 | +1% | Neutral | |
| $0.441 | $0.581 | $0.8211 | +17% | Neutral | |
| $0.5329 | $0.7219 | $1.05 | +45% | Bullish | |
| $0.5635 | $0.7825 | $1.18 | +58% | Bullish | |
| $0.5752 | $0.817 | $1.26 | +65% | Bullish | |
| $0.6069 | $0.8803 | $1.38 | +77% | Bullish | |
| $0.5766 | $0.8533 | $1.37 | +72% | Bullish | |
| $0.5921 | $0.8929 | $1.46 | +80% | Bullish | |
| $0.6612 | $1.02 | $1.69 | +105% | Bullish | |
| $0.9104 | $1.52 | $2.70 | +206% | Bullish | |
| $1.51 | $2.91 | $5.73 | +487% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.38 | $0.4962 | $0.5972 | +0.00% |
| September 2026 | $0.4026 | $0.4785 | $0.5864 | -3.56% |
| October 2026 | $0.4012 | $0.4806 | $0.5964 | +0.44% |
| November 2026 | $0.4011 | $0.4837 | $0.6063 | +0.64% |
| December 2026 | $0.3798 | $0.4608 | $0.5829 | -4.73% |
Click any year to see its month-by-month HRTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Heron Therapeutics, Inc.'s 2026 outlook centres on $0.4962, within a $0.38 to $0.5829 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, HRTX could reach as high as $0.6766, with a base case around $0.4998 and support toward $0.3924 — roughly +1% from $0.4962. Price action looks broadly range-bound.
Expect HRTX to range from $0.441 to $0.8211 through 2028. The $0.581 average target implies a +17% move from current prices. That is up +16% on the projected 2027 average. A consolidation phase looks the most probable path here.
The HRTX price prediction for 2029 points to an average of $0.7219 (low $0.5329, high $1.05) — a potential gain of +45% on today's $0.4962. Momentum favours further upside here.
In 2030, HRTX is projected to trade between $0.5635 and $1.18, averaging $0.7825 — a potential gain of +58% from today's $0.4962. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Heron Therapeutics, Inc.'s 2031 outlook centres on $0.817, within a $0.5752 to $1.26 range. That is up +4% on the projected 2030 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2032, HRTX could reach as high as $1.38, with a base case around $0.8803 and support toward $0.6069 — roughly +77% from $0.4962. Buyers look set to stay in control over this stretch.
Expect HRTX to range from $0.5766 to $1.37 through 2033. The $0.8533 average target implies a +72% move from current prices. That is -3% versus the projected 2032 average. Momentum favours further upside here.
The HRTX price prediction for 2034 points to an average of $0.8929 (low $0.5921, high $1.46) — a potential gain of +80% on today's $0.4962. Buyers look set to stay in control over this stretch.
In 2035, HRTX is projected to trade between $0.6612 and $1.69, averaging $1.02 — a potential gain of +105% from today's $0.4962. That is up +14% on the projected 2034 average. Momentum favours further upside here.
Heron Therapeutics, Inc.'s 2040 outlook centres on $1.52, within a $0.9104 to $2.70 range. That is up +50% on the projected 2035 average. That marks a +206% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, HRTX could reach as high as $5.73, with a base case around $2.91 and support toward $1.51 — roughly +487% from $0.4962. Momentum favours further upside here.
Investing $1,000 in HRTX today (≈ 2,015.316405 HRTX) could be worth
$5,874.33
+$4,874.33 (+487%) by 2050 · US Dollar
Based on the average projected HRTX price of $2.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HRTXwould be worth at today's price.
$1,000 invested in HRTX on Jul 31, 2025 (≈ 578.034676 HRTX) would be worth
$286.82
-$713.18 (-71.3%) today · 0.29× · US Dollar
Based on a HRTX entry price of $1.73 vs. today's $0.4962.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.46 | $1,078.7 | +7.9% |
| 1 month ago | $0.42 | $1,181.43 | +18.1% |
| 3 months ago | $1.27 | $390.71 | -60.9% |
| 6 months ago | $1.38 | $359.57 | -64.0% |
| 1 year ago | $1.73 | $286.82 | -71.3% |
| All time (5.0y) ago | $11.87 | $41.8 | -95.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HRTX forecast.
Our base-case forecast reaches $0.99 around 2035.
Implied market cap at $0.99: $187.39M
The multi-year forecast leans bullish over the longer horizon, with meaningful upside potential as you move into the 2030s and beyond. In 2030 the forecast shows an average price of $0.6887 with a min of $0.4687 and a max of $1.10, yielding a 44.7 value in ROI and a bullish sentiment. By 2040, the average is expected to be $1.14 with a max of $2.21 and a min of $0.602, delivering a 139.1 ROI and a bullish stance.
The long-run view extends to 2050, with an average of $2.01 and a max of $4.37, a min of $0.9046, and a 322.3 ROI, also labeled bullish. These forward-looking figures suggest substantial appreciation is possible over the extended horizon, but they come with inherent uncertainty and are not guarantees.
Tap a question to reveal the answer.
For 2030, the forecast shows a min of $0.4687, an average of $0.6887, and a max of $1.10, with a ROI of 44.7 and a BULLISH sentiment.
The forecast transitions to BULLISH from 2029 onward, with rising averages and higher potential price levels by 2030, 2040, and 2050, though early years show more modest returns and overall uncertainty means these are estimates, not guarantees.
Yes. The 2030 max is $1.10, and longer horizon figures show higher tops such as $2.21 by 2040 and up to $4.37 by 2050, indicating potential for prices above $1 in the forecast window.
The current price is $0.476 and the market cap is $90.1M.
The 30-day technical picture is NEUTRAL with RSI at 50. The stock trades near the SMA50 of $0.6298 and well below the SMA200 at $1.03, with a 30-day range from $0.3652 to $0.6205 and a near-term volatility profile of about 80%.
Heron Therapeutics, Inc. Community Discussion
0Share your Heron Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.